­
­
­
­

Inventi Impact: Urology & Nephrology

Articles

  • Inventi:hun/28071/19
    Abiraterone Acetate for Chemotherapynaive Metastatic Castration-Resistant Prostate Cancer: A Single-Centre Prospective Study of Efficacy, Safety, and Prognostic Factors
    Research 2019 : April - June
    Liancheng Fan, Baijun Dong, Chenfei Chi, Yanqing Wang, Yiming Gong, Jianjun Sha, Jiahua Pan, Xun Shangguan, Yiran Huang, Lixin Zhou, Wei Xue

    Background: To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with\nprednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer\n(mCRPC), and to identify predictive factors.\nMethods: We reviewed the medical records of 60 patients with chemotherapy-naive mCRPC at Renji Hospital who\nwere treated with AA plus prednisone (n = 43) or prednisone alone (n = 17). All patients were assessed for prostatespecific\nantigen (PSA) response, PSA progression-free survival (PSA PFS), radiographic progression-free survival (rPFS),\nand overall survival (OS). The ability of several parameters to predict PSA PFS, rPFS, and OS was studied....................

    How to Cite this Article
    CC Compliant Citation: Fan, Liancheng, et al. \"Abiraterone\nacetate for chemotherapy-naive metastatic castration-resistant\nprostate cancer: a single-centre prospective study of efficacy,\nsafety, and prognostic factors.\" BMC urology 18.1 (2018): 110,\nhttps://doi.org/10.1186/s12894-018-0416-6, http://\ncreativecommons.org/licenses/by/4.0/.
    Download Full Text